Decrease of transferrin receptor during mouse myeloid leukemia (Ml) cell differentiation

TL;DR: To study the phenomenon of blocked maturation, squamous carcinoma SqCC/Y1 cells were employed in culture and it was possible to demonstrate that physiological levels of retinoic acid and epidermal growth factor were capable of preventing the differentiation of these malignant keratinocytes into a mature tissue-like structure.

TL;DR: The current scientific evidence behind iron’s role as a protumoral agent, and the potential benefit of a state of iron depletion in patients with cancer are reviewed.

TL;DR: A 365-bp fragment from the 5' region of the human transferrin receptor gene has been subcloned and sequenced and contains a TATA box, several GC-rich regions, and is able to efficiently promote expression of the bacterial CAT gene in mouse 3T3 cells.

TL;DR: Findings demonstrate a new biochemical site of action for ACM and MCM and suggest that this activity is involved in the induction of terminal differentiation of HL-60 leukemia cells by these antitumor agents.

TL;DR: Two human lymphoblastoid cell lines and K-562 cells were found to take up radioiodinated transferrin and transferrin-bound iron in amounts comparable to reticulocytes, suggesting that only during erythroid differentiation do cells acquire a specific mechanism for removing iron from transferrin which is subject to feedback inhibition by heme.

TL;DR: It is indicated that one or more steps in cellular iron transport distal to transferrin binding is induced early by dimethyl sulfoxide and that ferritin may play an active role in iron delivery for heme synthesis.

TL;DR: In mammals, the major proportion of body iron is found as the iron porphyrin complexes, haemoglobin, myoglobin and a variety of haem-containing enzymes and many other iron proteins are found in the tissues, including metallo-flavoproteins and other enzymes in which iron is a cofactor.